Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss

[1]  Manju Patel,et al.  Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. , 2006, Ophthalmology.

[2]  D. Guyer,et al.  Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. , 2006, Ophthalmology.

[3]  J. Javitt,et al.  Comparison of Comorbid Conditions Between Wet AMD Patients and a Control Cohort in the Medicare Population , 2006 .

[4]  C. Gonzales.  ENHANCED EFFICACY ASSOCIATED WITH EARLY TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PEGAPTANIB SODIUM: An Exploratory Analysis , 2005, Retina.

[5]  Sanjay Sharma,et al.  Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. , 2005, Canadian Journal of Ophthalmology-journal Canadien D Ophtalmologie.

[6]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[7]  J. J. Wang,et al.  Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants , 2004, British Journal of Ophthalmology.

[8]  Emmett T. Cunningham,et al.  VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION CLINICAL TRIAL GROUP. PEGAPTANIB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2004 .

[9]  P. Kertes,et al.  Photodynamic Therapy of Subfoveal Choroidal Neovascularization with Verteporfin , 2004 .

[10]  P. Mitchell,et al.  Impact of bilateral visual impairment on health-related quality of life: the Blue Mountains Eye Study. , 2004, Investigative ophthalmology & visual science.

[11]  Sonia H Yoo,et al.  Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. , 2003, Survey of ophthalmology.

[12]  C. Owsley,et al.  Driving Habits and Health-Related Quality of Life in Patients with Age-Related Maculopathy , 2003, Optometry and vision science : official publication of the American Academy of Optometry.

[13]  Gisèle Soubrane,et al.  The burden of age-related macular degeneration: results of a cohort study in two French referral centres. , 2003, PharmacoEconomics.

[14]  B. Rovner,et al.  Effect of depression on vision function in age-related macular degeneration. , 2002, Archives of ophthalmology.

[15]  William J Feuer,et al.  Impact of visual function on computer task accuracy and reaction time in a cohort of patients with age-related macular degeneration. , 2002, American journal of ophthalmology.

[16]  R M Kaplan,et al.  Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. , 2001, Ophthalmology.

[17]  N. Bressler,et al.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. , 1999, Archives of ophthalmology.

[18]  A Hofman,et al.  Incidence and progression rates of age-related maculopathy: the Rotterdam Study. , 2001, Investigative ophthalmology & visual science.

[19]  C. Mangione,et al.  Influence of age-related maculopathy on visual functioning and health-related quality of life. , 1999, American journal of ophthalmology.

[20]  Stuart I. Brown,et al.  The psychosocial impact of macular degeneration. , 1998, Archives of ophthalmology.

[21]  Johannes R. Vingerling,et al.  The prevalence of age-related maculopathy in the Rotterdam Study. , 1995, Ophthalmology.

[22]  F. Ferris,et al.  Age-related macular degeneration and blindness due to neovascular maculopathy. , 1984, Archives of ophthalmology.

[23]  F L Ferris,et al.  Senile macular degeneration: review of epidemiologic features. , 1983, American journal of epidemiology.